Table 1.
DSB Repair Associated Experimental Evidence of the Combination Between HDACi and Chemo/Radiotherapy in Cancers
| Treatment | Regulation | Chemo/Radiosensitivity | Drug/Method | Cancer Type | Reference |
|---|---|---|---|---|---|
| SFN | HR, NHEJ | Chemo | Isothiocyanates | Colon cancer | [94–96] |
| HDAC1/2 inhibitor | HR | Chemo | Olaparib | Melanoma | [103] |
| Valproic acid | HR | Chemo/radio | Olaparib/ Irradiation | Prostate cancer | [58] |
| TSA | HR | Radio | Irradiation | Squamous carcinoma | [107] |
| TSA | P53 | Radio | Irradiation | Cervical cancer | [112] |
| TSA | HR | Radio | Irradiation | Squamous carcinoma | [110] |
| Sodium butyrate | NHEJ | Radio | Irradiation | Melanoma | [113] |
| Vorinostat | HR | Radio | Irradiation | Prostate and lung cancer | [115] |
| Valproic acid | HR, NHEJ | Radio | Irradiation | Glioma | [116] |
| LBH589 | γ-H2AX | Radio | Irradiation | Lung cancer | [118] |
| TSA | NHEJ | Radio | Irradiation | Lung cancer | [119] |
| Vorinostat | γ-H2AX | Radio | Irradiation | Breast cancer | [120] |
| Vorinostat | NHEJ | Radio | Irradiation | Osteosarcoma and rhabdomyosarcoma | [123] |
Abbreviations: SFN, sulforaphane; HDAC, histone deacetylase; TSA, trichostatin A; HR, homologous recombination; NHEJ, non-homologous end-joining.